1Schmidt D.Changes in the endometrium after tamoxifen therapy[J].Pathologe,2006,27(1):27-32.
2Tregon ML,Blumel JE,Tarin JJ,et al.The early response of the postmenopausal endometrium to tamoxifen:expression of estrogen receptors,progesterone receptors,and Ki-67 antigen[J].Menopause,2003,10(2):154-159.
3Wilder JL,Shajahan S,Khattar NH,et al.Tamoxifen-associated malignant endometrial tumors:pathologic features and expression_ of hormone receptors estrogen-alpha,estrogen-beta and progesterone; a case controlled study[J].Gynecol Oncol,2004,92(2):553-558.
4Klinge CM,Jernigan SC,Risinger KE,et al.The agonist activity of tamoxifen is inhibited by the short heterodimer partner orphan nuclear receptor in human endometrial cancer cells[J].Endocrinology,2002,143(3):853-867.
5Dhillon NK,Mudryj M.Ectopic expression of cyclin E in estrogen responsive cells abrogates antiestrogen mediated growth arrest[J].Oncogene,2002,21 (30):4626-4634.
6Zhang H,McElrath T,Tong W,et al.The molecular basis of tamoxifen induction of mouse uterine epithelial cell proliferation[J].J Endocrinol,2005,184(1):129-140.
7Vivacqua A,Bonofiglio D,Recchia AG,et al.The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells[J].Mol Endocrinol,2006,20(3):631-646.
8Liu X,Pisha E,Tonetti DA,et al.Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites[J].Chem Res Toxicol,2003,16(7):832-837.
9Kim SY,Suzuki N,Laxmi YR,et al.Genotoxic mechanism of tamoxifen in developing endometrial cancer[J].Drug Metab Rev,2004,36(2):199-218.
6Wilder JL, Shajahan S, Khattar NH, et al.Tamoxifen-associated malignant endometrial tumors: pathologic features and expression of hormone receptors estrogen-alpha, estrogen-beta and progesterone; a case controlled study[J], Gynecol Oncol, 2004, 92(2): 553-558.
7Cohen I. Endometrial pathologies associated with postmenopausal tamoxifen treatment[J]. Gynecol Oncol, 2004, 94(2): 256-266.
8Fung MF, Reid A, Faught W, et al. Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen[J]. Gynecol Oncol, 2003, 91:154-159.
9Cohen I, Azaria R, Bernheim J, et al. Risk factors of endometrial polyps resected from postmenopausal patients with breast carcinoma treated with tamoxifen[J]. Cancer, 2001, 92(5): 1151 - 1155.
10Egawa T, Toda K, Nemoto Y, et al. Pitavastatin ameliorates severe hepatic steatosis in aromatase-deficient(Ar-/-) mice[J]. Lipids, 2003, 38(5): 519-523.
